Your browser doesn't support javascript.
loading
Perivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases.
Andriuta, Daniela; Ottoy, Julie; Ruthirakuhan, Myuri; Feliciano, Ginelle; Dilliott, Allison A; Hegele, Robert A; Gao, Fuqiang; McLaughlin, Paula M; Rabin, Jennifer S; Wood Alexander, Madeline; Scott, Christopher J M; Yhap, Vanessa; Berezuk, Courtney; Ozzoude, Miracle; Swardfager, Walter; Zebarth, Julia; Tartaglia, M Carmela; Rogaeva, Ekaterina; Tang-Wai, David F; Casaubon, Leanne; Kumar, Sanjeev; Dowlatshahi, Dar; Mandzia, Jennifer; Sahlas, Demetrios; Saposnik, Gustavo; Fischer, Corinne E; Borrie, Michael; Hassan, Ayman; Binns, Malcolm A; Freedman, Morris; Chertkow, Howard; Finger, Elizabeth; Frank, Andrew; Bartha, Robert; Symons, Sean; Zetterberg, Henrik; Swartz, Richard H; Masellis, Mario; Black, Sandra E; Ramirez, Joel.
Afiliação
  • Andriuta D; Department of Neurology, Amiens University Medical Center, Amiens, France.
  • Ottoy J; Laboratoire de Neurosciences Fonctionnelles et Pathologies (UR UPJV 4559), Jules Verne University of Picardy, Amiens, France.
  • Ruthirakuhan M; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Feliciano G; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Dilliott AA; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Hegele RA; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Gao F; Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, Quebec, Canada.
  • McLaughlin PM; Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Toronto, Ontario, Canada.
  • Rabin JS; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Wood Alexander M; Nova Scotia Health, Halifax, Nova Scotia, Canada.
  • Scott CJM; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Yhap V; Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Berezuk C; Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada.
  • Ozzoude M; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Swardfager W; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Zebarth J; Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada.
  • Tartaglia MC; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Rogaeva E; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Tang-Wai DF; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Casaubon L; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Kumar S; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Dowlatshahi D; Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Mandzia J; Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Sahlas D; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Saposnik G; Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Fischer CE; Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Borrie M; Department of Psychiatry, Adult Neurodevelopment and Geriatric Psychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Hassan A; University of Ottawa Brain and Mind Research Institute and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Binns MA; Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Toronto, Ontario, Canada.
  • Freedman M; Division of Neurology, Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Chertkow H; Li Ka Shing Knowledge Institute, and Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Finger E; Li Ka Shing Knowledge Institute, and Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Frank A; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Bartha R; Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Toronto, Ontario, Canada.
  • Symons S; Division of Neurology, Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Zetterberg H; Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario, Canada.
  • Swartz RH; Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada.
  • Masellis M; Division of Biostatistics, Dalla Lana School of Public Health, Toronto, Ontario, Canada.
  • Black SE; Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada.
  • Ramirez J; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Alzheimers Dement ; 20(8): 5800-5808, 2024 08.
Article em En | MEDLINE | ID: mdl-38961774
ABSTRACT

INTRODUCTION:

We investigated the effect of perivascular spaces (PVS) volume on speeded executive function (sEF), as mediated by white matter hyperintensities (WMH) volume and plasma glial fibrillary acidic protein (GFAP) in neurodegenerative diseases.

METHODS:

A mediation analysis was performed to assess the relationship between neuroimaging markers and plasma biomarkers on sEF in 333 participants clinically diagnosed with Alzheimer's disease/mild cognitive impairment, frontotemporal dementia, or cerebrovascular disease from the Ontario Neurodegenerative Disease Research Initiative.

RESULTS:

PVS was significantly associated with sEF (c = -0.125 ± 0.054, 95% bootstrap confidence interval [CI] [-0.2309, -0.0189], p = 0.021). This effect was mediated by both GFAP and WMH.

DISCUSSION:

In this unique clinical cohort of neurodegenerative diseases, we demonstrated that the effect of PVS on sEF was mediated by the presence of elevated plasma GFAP and white matter disease. These findings highlight the potential utility of imaging and plasma biomarkers in the current landscape of therapeutics targeting dementia. HIGHLIGHTS Perivascular spaces (PVS) and white matter hyperintensities (WMH) are imaging markers of small vessel disease. Plasma glial fibrillary protein acidic protein (GFAP) is a biomarker of astroglial injury. PVS, WMH, and GFAP are relevant in executive dysfunction from neurodegeneration. PVS's effect on executive function was mediated by GFAP and white matter disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Biomarcadores / Doenças Neurodegenerativas / Função Executiva / Substância Branca / Sistema Glinfático / Proteína Glial Fibrilar Ácida Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Biomarcadores / Doenças Neurodegenerativas / Função Executiva / Substância Branca / Sistema Glinfático / Proteína Glial Fibrilar Ácida Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article